Janssen HLA - Search Results

1

Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Papatheodoridis GV, et al. Among authors: janssen hla. J Hepatol. 2020 Nov;73(5):1037-1045. doi: 10.1016/j.jhep.2020.06.011. Epub 2020 Jun 16. J Hepatol. 2020. PMID: 32553667

2

Suicide associated with alfa-interferon therapy for chronic viral hepatitis.

Janssen HL, Brouwer JT, van der Mast RC, Schalm SW. Janssen HL, et al. J Hepatol. 1994 Aug;21(2):241-3. doi: 10.1016/s0168-8278(05)80402-7. J Hepatol. 1994. PMID: 7989716

3

Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial.

Janssen HL, Berk L, Heijtink RA, ten Kate FJ, Schalm SW. Janssen HL, et al. Hepatology. 1993 Mar;17(3):383-8. Hepatology. 1993. PMID: 8444411 Clinical Trial.

4

Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.

Janssen HL, Schalm SW, Berk L, de Man RA, Heijtink RA. Janssen HL, et al. J Hepatol. 1993;17 Suppl 3:S47-51. doi: 10.1016/s0168-8278(05)80423-4. J Hepatol. 1993. PMID: 8509639

5

Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).

Janssen HL, Gerken G, Carreño V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Janssen HL, et al. Hepatology. 1999 Jul;30(1):238-43. doi: 10.1002/hep.510300113. Hepatology. 1999. PMID: 10385662 Clinical Trial.

6

The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome.

Tang TJ, Batts KP, de Groen PC, van Hoek B, Haagsma EB, Hop WC, Janssen HL. Tang TJ, et al. J Hepatol. 2001 Sep;35(3):338-43. doi: 10.1016/s0168-8278(01)00131-3. J Hepatol. 2001. PMID: 11592594

7

Combination and newer therapies for chronic hepatitis B.

Schalm SW, De Man RA, Janssen HL. Schalm SW, et al. J Gastroenterol Hepatol. 2002 Dec;17 Suppl 3:S338-41. doi: 10.1046/j.1440-1746.17.s3.24.x. J Gastroenterol Hepatol. 2002. PMID: 12472960

8

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.

van Nunen AB, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW. van Nunen AB, et al. Gut. 2003 Mar;52(3):420-4. doi: 10.1136/gut.52.3.420. Gut. 2003. PMID: 12584227 Free PMC article.

9

Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression.

Janssen HL, Higuchi H, Abdulkarim A, Gores GJ. Janssen HL, et al. J Hepatol. 2003 Sep;39(3):414-20. doi: 10.1016/s0168-8278(03)00265-4. J Hepatol. 2003. PMID: 12927928

10

Pretreatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection.

Vrolijk JM, Kwekkeboom J, Janssen HL, Hansen BE, Zondervan PE, Osterhaus AD, Schalm SW, Haagmans BL. Vrolijk JM, et al. J Infect Dis. 2003 Nov 15;188(10):1528-32. doi: 10.1086/379334. Epub 2003 Oct 20. J Infect Dis. 2003. PMID: 14624378

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

604 results

Search Page

Filters